Authors: M. Kozárová; Z. Kozelová Authors‘ workplace: Univerzita Pavla Jozefa Šafárika a Univerzitná nemocnica L. Pasteura, Košice, IV. interná klinika, Prednosta: MUDr. Martin Javorský, PhD., MPH Published in: Prakt. Lék. 2026; 106(1): 19-24 Category: Of different specialties
The ESC/EAS European guidelines for the management of dyslipidemias and prevention of cardiovascular disease have undergone significant developments in recent years. The aim of this review is to compare the 2019, 2021 and 2025 guidelines, focusing on SCORE2 and SCORE2-OP scoring systems, LDL-cholesterol targets, the use of PCSK9 inhibitors, inclisiran in the treatment of dyslipidemias, and the role of lipoprotein(a) in cardiovascular risk stratification. The update of the ESC/EAS guidelines from 2019 to 2025 reflects a shift towards more aggressive, individualized and early treatment of dyslipidemias. Particular emphasis is placed on combination lipid-lowering therapy and on the identification of patients with high genetic risk (familial hyperchoelsterolemia), with the aim of further residual cardiovascular risk reduction.
lipoprotein(a) – cardiovascular risk – LDL-cholesterol – PCSK9 inhibitors – dyslipidemias
1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
2. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
3. Mach F, Baigent C, Catapano AL, et al. Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025; 46(42): 4359–4378.
4. Kronenberg F, Bedlington N, Ademi Z, et al. Brussels international declaration on lipoprotein(a) testing and management. Atherosclerosis. 2025; 406 : 119218.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
